MDS as an Immunoresponsive Disease

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

When added to tivozanib, nivolumab did not lead to improved clinical outcomes in metastatic renal cell carcinoma.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.

The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.